PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Pevonedistat

Drugs in development · updated 30 October 2026

Pevonedistat: clinical trials and development status

NLM verified identityNot approved in the USNo EMA authorisationEstimated launch Dec 2027 – Oct 2028 (Phuturdex estimate)

As of 30 October 2026 Pevonedistat is in 7 active clinical trials (recruiting or ongoing, phases I–III) for 22 diseases. The most advanced phase is III.

7Active trials
IIIMost advanced phase
22Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Pevonedistat and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Acute myeloid leukemiaIII2NCT04090736
LeukemiaIII1NCT04090736
Atypical chronic myeloid leukemiaI–II1NCT03862157
CholangiocarcinomaII1NCT04175912
Chronic myelomonocytic leukemiaI–II1NCT03862157
Chronic neutrophilic leukemiaI–II1NCT03862157
Hepatocellular carcinomaII1NCT04175912
Hypereosinophilic syndromeI–II1NCT03862157
Lung neoplasmII1NCT03965689
Myelodysplastic SyndromesI–II1NCT03862157
MyelofibrosisI–II1NCT03862157
Myeloproliferative disordersI–II1NCT03862157
Polycythemia veraI–II1NCT03862157
Thrombocythemia, EssentialI–II1NCT03862157
ThrombocytosisI–II1NCT03862157
B-cell prolymphocytic leukemiaI1NCT03479268
Chronic lymphocytic leukemiaI1NCT03479268
Diffuse large B-cell lymphomaI1NCT03479268
Follicular lymphomaI1NCT03479268
Lymphoma, B-Cell, Marginal ZoneI1NCT03479268
Mantle cell lymphomaI1NCT03479268
Non-Hodgkin lymphomaI1NCT03479268

Everything on Pevonedistat

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch